Sucroferric oxyhydroxide treatment improves phosphorus control in patients on hemodialysis
Click Here to Manage Email Alerts
Sucroferric oxyhydroxide treatment in patients on hemodialysis resulted in improved serum phosphorus control, according to a speaker at the virtual National Kidney Foundation Spring Clinical Meetings.
“Current [Kidney Disease Outcomes Quality Initiative] KDOQI guidelines recommend limiting calcium-based phosphate binders in dialysis patients,” Anjay Rastogi, MD, PhD, of the University of California, Los Angeles, and colleagues wrote in the abstract. “This current analysis examined patients who were switched to the non-calcium, iron-based phosphate binder, sucroferric oxyhydroxide.”
A total of 66 adult patients on hemodialysis at DaVita Inc. were prescribed a switch in phosphate binder therapy between May 2014 and September 2018 from calcium acetate (CaAc) to sucroferric oxyhydroxide (SO) for 1 year. Rastogi and colleagues compared changes in mineral bone disease markers, phosphate binder pill burden and the proportion of patients achieving the target serum phosphorus (no more than 5.5 mg/dL) between 3 months of baseline CaAc and 1 year of SO therapy follow-up.
Primary outcomes included longitudinal changes in patients achieving the KDOQI-defined serum phosphate target (no more than 5.5 mg/dL), achieving KDIGO-defined serum phosphorus target (no more than 4.5 mg/dL) and phosphate binder pill burden.
Results found that with a treatment of 9.6 CaAc pills per day, 30% of patients had a serum phosphate level of no more than 5.5 mg/dL. With the SO treatment, serum phosphate improved from 30.3% to 56% at SO months 3 and 5. Patients were prescribed 4.6 to 5.7 fewer phosphate binder pills per day on SO treatment.
During follow-up, there was a significant trend toward decreases in the mean serum calcium from 9.1 mg/dL at baseline to 8.9 mg/dL at months 10 through 12, according to researchers.
“The results of this analysis, along with other real-world data and clinical trial data in dialysis patients, confirm sucroferric oxyhydroxide’s ability to decrease serum phosphorus levels in dialysis patients along with its lower pill burden compared to other commonly used phosphate binders,” Rastogi and colleagues wrote. – by Erin T. Welsh
Reference:
Rastogi A, et al. Abstract #211. Presented at: National Kidney Foundation Spring Clinical Meetings; March 26-29, 2020 (virtual meeting).
Disclosure: The study was funded by Fresenius Medical Care.